News

Public · Published

Co-Diagnostics - Cosara To Initiate Sales Activities Across India And South Asia

Co-Diagnostics said Cosara will begin sales activities across India and South Asia with support from a direct sales team. The company also said it anticipates CDSCO clearance and a commercial launch in India before year-end 2026. CDSCO is India's drug regulator.

Published:

Updated:

What happened

Co-Diagnostics said Cosara will begin sales activities across India and South Asia with support from a direct sales team. The company also said it anticipates CDSCO clearance and a commercial launch in India before year-end 2026. CDSCO is India's drug regulator.

Confirmed

Global impact / market context

A commercial launch would move Co-Diagnostics from development spending toward possible test revenue in India. Building a direct sales team adds costs before sales begin. Investors would watch whether approvals arrive on schedule and whether revenue covers the added selling expense.

Analyst inference

Co-Diagnostics is a small diagnostics company, so a single large market can matter a lot. India and South Asia offer volume, but pricing and tender-based purchasing can pressure profit per sale. Regulatory timing is the main swing factor for the stock.

Analyst inference

What to watch

  1. Co-Diagnostics and Cosara expect regulatory approval of the Cosara PCR MTB test in the fourth quarter of 2026. PCR is a lab technique that copies genetic material so infections can be detected. Confirmed
  2. Watch whether the CDSCO clearance arrives before year-end 2026 as anticipated, because a delay would push back the commercial launch and any related test revenue in India. Analyst inference
  3. Track sales spending and early order volume after launch, since direct sales costs would weigh on cash available if revenue from India and South Asia ramps more slowly than planned. Analyst inference

Evidence

  • Original source link unavailable